TY - JOUR
T1 - Management of Newly Diagnosed Myeloma
AU - Rajkumar, S. Vincent
AU - Palumbo, Antonio
N1 - Funding Information:
SVR has received research support to cover the cost of clinical trials at Mayo Clinic from Celgene Corporation. AP has received scientific advisory board and lecture fees from Pharmion, Celgene, and Janssen-Cilag. Also supported by grants CA 62242, CA107476, CA 100080, and CA 93842 from the National Cancer Institute, Bethesda, Maryland, USA to SVR. Supported in part by the Università degli Studi di Torino; Fondazione Neoplasie Sangue Onlus, Associazione Italiana Leucemie, Compagnia di S Paolo, Fondazione Cassa di Risparmio di Torino, Ministero dell'Università e della Ricerca (MIUR), and Consiglio Nazionale delle Ricerche (CNR); Italy.
PY - 2007/12
Y1 - 2007/12
N2 - The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.
AB - The treatment of multiple myeloma has changed dramatically in the last decade with the introduction of thalidomide, bortezomib, and lenalidomide. Patients eligible for autologous stem cell transplantation (ASCT) are treated with non-alkylating agent-containing regimens as initial therapy; typically thalidomide-dexamethasone or lenalidomide-dexamethasone. For patients not eligible for ASCT, the current standard of care is melphalan, prednisone, and thalidomide. Ongoing trials will soon assess if combinations including melphalan and prednisone plus bortezomib or MP plus lenalidomide may be considered an attractive option. Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments.
UR - http://www.scopus.com/inward/record.url?scp=35748974554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35748974554&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2007.08.008
DO - 10.1016/j.hoc.2007.08.008
M3 - Review article
C2 - 17996592
AN - SCOPUS:35748974554
SN - 0889-8588
VL - 21
SP - 1141
EP - 1156
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 6
ER -